Quest Diagnostics (DGX)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$237.14-0.94%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · DGX
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $237 DGX trades at 22× p/e, below its 23× p/e peer median, but our blended $206 fair value sits below the price. We hold it with medium confidence: our number sits below the analyst range. Analysts target $232–$260. Note: our $206 fair value sits below the entire analyst range ($232–$260). Even valued only for durable growth at sustainable margins, it's worth about $255 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $247.50 | — | — | Analyst | high |
| dcf fcfe | 12M | $317.54 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $395.88 | — | — | Hist. CAGR | high |
| ddm gordon | 12M | $66.71 | — | — | TTM | high |
| graham number | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Around the middle on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$232.00 – $260.00 (median $247.50) · 6 analysts · as of 2026-07-29
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 9% over what the business is worth with no growth; closing that gap needs roughly — years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $9.86/sh owner earnings.
Roughly priced in line with peers.
Richer than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $129.28 |
| — |
| — |
| TTM |
| high |
| Peer EV/EBITDA | 12M | $209.25 | 12.7 | 20.18 | TTM | high |
| Peer P/FCF | 12M | $232.45 | 21.3 | 10.89 | TTM | high |
| Peer P/E | 12M | $220.78 | 18.7 | 11.78 | ntm analyst | high |
| Peer P/S | 12M | $391.99 | 3.8 | 103.21 | TTM | high |
| PEG | 12M | $237.94 | 22.4 | 10.64 | TTM | high |
| residual income | 12M | $91.18 | — | — | TTM | high |
| Own P/E history | 12M | $211.27 | 19.9 | 10.64 | TTM | high |
| triangulated | 12M | $254.69 | 22.9 | 11.12 | Triangulated | high |
| Peer P/FCF | 3Y | $322.99 | 21.3 | 15.14 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $235.70 | 18.7 | 12.57 | Analyst | medium |
| Peer P/S | 3Y | $444.54 | 3.8 | 117.05 | guidance | medium |
| PEG | 3Y | $281.18 | 22.4 | 12.57 | Analyst | medium |
| Own P/E history | 3Y | $249.67 | 19.9 | 12.57 | Analyst | medium |
| Peer P/FCF | 5Y | $402.19 | 21.3 | 18.85 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $247.26 | 18.7 | 13.19 | Analyst | high |
| Peer P/S | 5Y | $466.34 | 3.8 | 122.79 | guidance | high |
| PEG | 5Y | $294.97 | 22.4 | 13.19 | Analyst | high |
| Own P/E history | 5Y | $261.91 | 19.9 | 13.19 | Analyst | high |